Business Directory

General

PrismRA is a molecular signature response classifier (MSRC) that uses gene expression features, clinical features and anti-cyclic citrullinated protein (anti-CCP) antibody to detect a signature of non-response to tumor necrosis factor-α inhibitors (TNFi) for patients with rheumatoid arthritis. PrismRA predicts the patient’s likelihood of inadequately responding to all TNFi therapies. Response is defined as achieving ACR50 at 6 months. The PrismRA result is reported on a continuous 1 to 25 scale. The higher the score, the more likely the patient will have an inadequate response to TNFi therapies; the lower the score, the less likely the patient will have an inadequate response to TNFi therapies. However, a low score does not ensure a positive response to TNFi therapies.

PrismRA for Patients

How PrismRA Helps You
Get PrismRA
The PrismRA Result
Find a Provider
Affordability
Join the Newsletter
Billing FAQs

For Physicians

Clinical Content
The PrismRA Solution
PrismRA Development
The PrismRA Result Report
Ordering PrismRA
Publications & Tech Specs

Resources

Patient Brochure
Folleto Para Pacientes
Billing Brochure
Folleto Para Facturación
Financial Assistance
Patient Billing Portal
How to Talk to Your Doctor
Global Healthy Living Foundation

Scipher Medicine

Contact Us
PrismRA Lab Certifications
Scipher Lab Service Guide
Notice of Privacy Practices
Privacy Policy
Terms of Use
Cookies Acknowledgement
Patient Opt-Out Information
Right to Receive a Good Faith Estimate
Notice of Nondiscrimination